Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Nübling CM[au]:

Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes. Hassemer M et al. Virology. (2017)

Standardization of NAT for Blood-Borne Pathogens. Baylis SA et al. Transfus Med Hemother. (2015)

Establishment of the Ph. Eur. Hepatitis A virus RNA for NAT testing BRP batch 1. Chudy M et al. Pharmeur Bio Sci Notes. (2017)

Search results

Items: 44

1.

Standardization of Nucleic Acid Tests: the Approach of the World Health Organization.

Baylis SA, Wallace P, McCulloch E, Niesters HGM, Nübling CM.

J Clin Microbiol. 2019 Jan 2;57(1). pii: e01056-18. doi: 10.1128/JCM.01056-18. Print 2019 Jan. Review.

PMID:
30257900
2.

External Quality Assessment (EQA) of Molecular Detection of Zika Virus: Value of the 1st World Health Organization International Standard.

Baylis SA, McCulloch E, Wallace P, Donoso Mantke O, Niedrig M, Blümel J, Yue C, Nübling CM.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01997-17. doi: 10.1128/JCM.01997-17. Print 2018 Mar. No abstract available.

3.

Establishment of the Ph. Eur. Hepatitis A virus RNA for NAT testing BRP batch 1.

Chudy M, Nübling CM, Blümel J, Daas A, Costanzo A.

Pharmeur Bio Sci Notes. 2017;2017:29-43.

PMID:
29017703
4.

Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes.

Hassemer M, Finkernagel M, Peiffer KH, Glebe D, Akhras S, Reuter A, Scheiblauer H, Sommer L, Chudy M, Nübling CM, Hildt E.

Virology. 2017 Feb;502:1-12. doi: 10.1016/j.virol.2016.12.003. Epub 2016 Dec 9.

5.

Hepatitis E viral loads in plasma pools for fractionation.

Baylis SA, Corman VM, Ong E, Linnen JM, Nübling CM, Blümel J.

Transfusion. 2016 Oct;56(10):2532-2537. doi: 10.1111/trf.13722. Epub 2016 Jul 24.

PMID:
27453197
6.

Viral nucleic acids in human plasma pools.

Zhang W, Li L, Deng X, Blümel J, Nübling CM, Hunfeld A, Baylis SA, Delwart E.

Transfusion. 2016 Sep;56(9):2248-55. doi: 10.1111/trf.13692. Epub 2016 Jun 16.

PMID:
27306718
7.

Treating snake bites--a call for partnership.

Rägo L, Marroquin AM, Nübling CM, Sawyer J.

Lancet. 2015 Dec 5;386(10010):2252. doi: 10.1016/S0140-6736(15)01103-4. No abstract available.

PMID:
26681285
8.

Standardization of NAT for Blood-Borne Pathogens.

Baylis SA, Chudy M, Nübling CM.

Transfus Med Hemother. 2015 Jul;42(4):211-8. doi: 10.1159/000435872. Epub 2015 Jul 1. Review.

9.

World Health Organization International Standard To Harmonize Assays for Detection of Mycoplasma DNA.

Nübling CM, Baylis SA, Hanschmann KM, Montag-Lessing T, Chudy M, Kreß J, Ulrych U, Czurda S, Rosengarten R; Mycoplasma Collaborative Study Group.

Appl Environ Microbiol. 2015 Sep 1;81(17):5694-702. doi: 10.1128/AEM.01150-15. Epub 2015 Jun 12.

10.

Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples.

Laperche S, Nübling CM, Stramer SL, Brojer E, Grabarczyk P, Yoshizawa H, Kalibatas V, El Elkyabi M, Moftah F, Girault A, van Drimmelen H, Busch MP, Lelie N.

Transfusion. 2015 Oct;55(10):2489-98. doi: 10.1111/trf.13179. Epub 2015 May 27.

11.

[Legal basis and practice of examination of critical in vitro diagnostic devices].

Nübling CM, Nick S.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Oct;57(10):1203-8. doi: 10.1007/s00103-014-2038-9. German.

PMID:
25168841
12.

Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany.

Chudy M, Kress J, Halbauer J, Heiden M, Funk MB, Nübling CM.

Transfus Med Hemother. 2014 Feb;41(1):45-51. doi: 10.1159/000357103. Epub 2013 Dec 19.

13.

Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel.

Chudy M, Scheiblauer H, Hanschmann KM, Kress J, Nick S, Wend U, Schüttler C, Nübling CM, Gerlich WH.

J Clin Virol. 2013 Sep;58(1):47-53. doi: 10.1016/j.jcv.2013.06.011. Epub 2013 Jul 3. Erratum in: J Clin Virol. 2013 Nov;58(3):598-9.

PMID:
23829967
14.

[The ways of harmonization of clinical laboratory measurement techniques].

Miller WG, Myers GL, Gantzer ML, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Stanley GL, Nubling CM, Sturgeon CM.

Klin Lab Diagn. 2013 Feb;(2):54-61. Russian.

PMID:
23808013
15.

How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing.

Müller B, Nübling CM, Kress J, Roth WK, De Zolt S, Pichl L.

Transfusion. 2013 Oct;53(10 Pt 2):2422-30. doi: 10.1111/trf.12298. Epub 2013 Jun 19.

PMID:
23782012
16.

World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA.

Baylis SA, Blümel J, Mizusawa S, Matsubayashi K, Sakata H, Okada Y, Nübling CM, Hanschmann KM; HEV Collaborative Study Group.

Emerg Infect Dis. 2013 May;19(5):729-35. doi: 10.3201/eid1905.121845.

17.

First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA.

Chudy M, Hanschmann KM, Kress J, Nick S, Campos R, Wend U, Gerlich W, Nübling CM.

J Clin Virol. 2012 Dec;55(4):303-9. doi: 10.1016/j.jcv.2012.08.013. Epub 2012 Sep 12.

PMID:
22981623
18.

Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets.

Chudy M, Weber-Schehl M, Pichl L, Jork C, Kress J, Heiden M, Funk MB, Nübling CM.

Transfusion. 2012 Feb;52(2):431-9. doi: 10.1111/j.1537-2995.2011.03281.x. Epub 2011 Aug 2.

PMID:
21810100
19.

Roadmap for harmonization of clinical laboratory measurement procedures.

Greg Miller W, Myers GL, Lou Gantzer M, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Lo SF, Nübling CM, Sturgeon CM.

Clin Chem. 2011 Aug;57(8):1108-17. doi: 10.1373/clinchem.2011.164012. Epub 2011 Jun 15.

20.

Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance.

Baylis SA, Hanschmann KM, Blümel J, Nübling CM; HEV Collaborative Study Group.

J Clin Microbiol. 2011 Apr;49(4):1234-9. doi: 10.1128/JCM.02578-10. Epub 2011 Feb 9.

21.

Tissue donation and virus safety: more nucleic acid amplification testing is needed.

Pruss A, Caspari G, Krüger DH, Blümel J, Nübling CM, Gürtler L, Gerlich WH.

Transpl Infect Dis. 2010 Oct;12(5):375-86. doi: 10.1111/j.1399-3062.2010.00505.x. Review.

PMID:
20412535
22.

First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.

Schmidt M, Korn K, Nübling CM, Chudy M, Kress J, Horst HA, Geusendam G, Hennig H, Sireis W, Rabenau HF, Doerr HW, Berger A, Hourfar MK, Gubbe K, Karl A, Fickenscher H, Tischer BK, Babiel R, Seifried E, Gürtler L.

Transfusion. 2009 Sep;49(9):1836-44. doi: 10.1111/j.1537-2995.2009.02203.x. Epub 2009 May 11.

PMID:
19453990
23.

Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions.

Nübling CM, Heiden M, Chudy M, Kress J, Seitz R, Keller-Stanislawski B, Funk MB.

Transfusion. 2009 Sep;49(9):1850-8. doi: 10.1111/j.1537-2995.2009.02212.x. Epub 2009 May 14.

PMID:
19453976
24.

Consistency of quantitation of HCV genotype 4 from egypt across three HCV-RNA amplification assays.

El Sharkawi FZ, Chudy M, Hanschmann KM, Kress J, Nübling CM.

J Med Virol. 2008 Dec;80(12):2086-91. doi: 10.1002/jmv.21325.

PMID:
19040283
25.

Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.

Nübling CM, Unkelbach U, Chudy M, Seitz R.

Transfusion. 2008 May;48(5):822-6. doi: 10.1111/j.1537-2995.2007.01612.x. Epub 2008 Jan 15.

PMID:
18208414
26.

West Nile virus and blood product safety in Germany.

Pfleiderer C, Blümel J, Schmidt M, Roth WK, Houfar MK, Eckert J, Chudy M, Menichetti E, Lechner S, Nübling CM.

J Med Virol. 2008 Mar;80(3):557-63. doi: 10.1002/jmv.21110.

PMID:
18205233
27.

The harmonization of the regulation of blood products: a European perspective.

Seitz R, Heiden M, Nübling CM, Unger G, Löwer J.

Vox Sang. 2008 May;94(4):267-76. doi: 10.1111/j.1423-0410.2007.01026.x. Epub 2008 Jan 2. Review.

PMID:
18179678
29.

Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.

Nübling CM, Chudy M, Volkers P, Löwer J.

Transfusion. 2006 Nov;46(11):1886-91.

PMID:
17076842
30.

Molecular epidemiology of West Nile Virus in humans.

Pfleiderer C, König C, Chudy M, Schmidt M, Roth WK, Nübling CM.

Dev Biol (Basel). 2006;126:197-201; discussion 326-7.

PMID:
17058495
31.

Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests.

Schmidt M, Nübling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK.

Vox Sang. 2006 Oct;91(3):237-43.

PMID:
16958836
32.

Hepatitis B virus genotype G monoinfection and its transmission by blood components.

Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, Hourfar MK, Seifried E, Roth WK, Grünelt E, Nübling CM.

Hepatology. 2006 Jul;44(1):99-107.

PMID:
16799987
34.

Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.

Nübling CM, Unger G, Chudy M, Raia S, Löwer J.

Transfusion. 2002 Aug;42(8):1037-45.

PMID:
12385416
35.

Hepatitis A virus infection in tamarins: experimental transmission via contaminated factor VIII concentrates.

Chudy M, Stahl-Hennig C, Berger A, Nübling CM, Hunsmann G, Rabenau HF, Löwer J.

J Infect Dis. 2002 Apr 15;185(8):1170-3. Epub 2002 Mar 20.

PMID:
11930328
36.

Human T-cell lymphocytotrophic virus prevalence in German blood donors and "at-risk" groups.

Nübling M, Nübling CM, Seifried E, Weichert W, Löwer J.

Vox Sang. 2001 Oct;81(3):204-6. No abstract available.

PMID:
11703866
37.

Causality assessment of suspected virus transmission by human plasma products.

Schosser R, Keller-Stanislawski B, Nübling CM, Löwer J.

Transfusion. 2001 Aug;41(8):1020-9.

PMID:
11493734
38.

Hepatitis C virus transmission through quarantine fresh-frozen plasma.

Humpe A, Legler TJ, Nübling CM, Riggert J, Unger G, Wolf C, Heermann KH, Köhler M.

Thromb Haemost. 2000 Nov;84(5):784-8.

PMID:
11127856
39.

Validation of HCV-NAT assays and experience with NAT application for blood screening in Germany.

Nübling CM, Chudy M, Löwer J.

Biologicals. 1999 Dec;27(4):291-4.

PMID:
10686055
40.

A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool.

Chudy M, Budek I, Keller-Stanislawski B, McCaustland KA, Neidhold S, Robertson BH, Nübling CM, Seitz R, Löwer J.

J Med Virol. 1999 Feb;57(2):91-9.

PMID:
9892390
41.

Frequencies of GB virus C/hepatitis G virus genomes and of specific antibodies in German risk and non-risk populations.

Nübling CM, Bialleck H, Fürsch AJ, Scharrer I, Schramm W, Seifried E, Schmidt U, Staszewski S, Löwer J.

J Med Virol. 1997 Nov;53(3):218-24.

PMID:
9365885
42.

GB-C genomes in a high-risk group, in plasma pools, and in intravenous immunoglobulin.

Nübling CM, Lŏwer J.

Lancet. 1996 Jan 6;347(8993):68. No abstract available.

PMID:
8531587
43.

Hepatitis C transmission associated with intravenous immunoglobulins.

Nübling CM, Willkommen H, Löwer J.

Lancet. 1995 May 6;345(8958):1174. No abstract available.

PMID:
7536875
44.

Hepatitis C virus antibody prevalence among human immunodeficiency virus-1-infected individuals: analysis with different test systems.

Nübling CM, von Wangenheim G, Staszewski S, Löwer J.

J Med Virol. 1994 Sep;44(1):49-53.

PMID:
7798885

Supplemental Content

Loading ...
Support Center